La Jolla Pharmaceutical Co.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -4.11%75.230.0%$2385.15m
NVAXNovavax, Inc. 8.28%170.1999.2%$1263.64m
GILDGilead Sciences, Inc. -2.37%69.201.0%$527.29m
AMGNAmgen, Inc. -0.97%241.241.3%$510.65m
REGNRegeneron Pharmaceuticals, Inc. -2.53%632.012.5%$463.54m
SRNESorrento Therapeutics, Inc. 6.54%13.681.8%$444.53m
BNTXBioNTech SE -2.54%81.060.0%$402.40m
VRTXVertex Pharmaceuticals, Inc. -1.43%271.771.9%$379.08m
VXRTVaxart, Inc. 10.06%9.790.0%$329.51m
ILMNIllumina, Inc. 2.52%403.583.5%$327.99m
BIIBBiogen, Inc. -0.08%275.871.6%$326.68m
IBIOiBio, Inc. 1.03%4.441.8%$184.72m
EBSEmergent BioSolutions, Inc. 8.30%132.816.4%$175.25m
SGENSeattle Genetics, Inc. -1.12%163.236.1%$173.16m
ALXNAlexion Pharmaceuticals, Inc. -2.18%102.932.0%$171.16m

Company Profile

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla’s investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.